Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels

In the treatment of head and neck cancer, cisplatin is often used as a therapeutic agent; however, its efficacy is limited and it can cause renal dysfunction as an adverse effect. For this reason, the use of cisplatin is limited in elderly patients with reduced renal function. Recently, artemisinin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Hiroki, Yoshikawa, Kazuhiro, Shimada, Akiko, Sano, Rui, Inukai, Daisuke, Yamanaka, Shunpei, Suzuki, Susumu, Ueda, Ryuzo, Ueda, Hiromi, Fujimoto, Yasushi, Ogawa, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308456/
https://www.ncbi.nlm.nih.gov/pubmed/37350399
http://dx.doi.org/10.3892/or.2023.8591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308456/
https://www.ncbi.nlm.nih.gov/pubmed/37350399
http://dx.doi.org/10.3892/or.2023.8591

Ejemplares similares